Nonexudative Age-related Macular Degeneration Clinical Trial
Official title:
A Pilot Study to Evaluate Clinical Outcomes of Photobiomodulation in Patients With Age Related Macular Degeneration of the Dry Type.
The purpose of this study is to evaluate clinical outcomes of Photobiomodulation treatment on
patients with dry Age Related Macular Degeneration (AMD).
Photobiomodulation is the use of non thermal, non laser light of specific wavelengths and
energy directly on the eye to improve retinal function and delay AMD progression.
This is a prospective 2 center phase 2 clinical pilot study with no placebo group.
Dry AMD is a progressive sight threatening disease affecting central acute vision. Dry AMD
may progress to the wet form where leaking and bleeding in the retina can cause sudden severe
visual loss.
There are no proven active treatments for Dry AMD. Dry AMD accounts for over 80% of AMD
cases.
There are estimated to be 30 million people afflicted with AMD by the year 2020 in North
America.
Photobiomodulation in this study is utilised by using two devices that are already approved
for other indications by the FDA and Health Canada.
Photobiomodulation is a novel clinical application for treating dry AMD. As this is a pilot
study there is no placebo or control group.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01922128 -
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT02051998 -
Directional Spread in Geographic Atrophy
|
||
| Completed |
NCT05703867 -
Transpalpebral Microcurrent Stimulation for the Improvement of Visual Acuity in Patients With Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT04723160 -
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
|
||
| Recruiting |
NCT05447650 -
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
|
N/A |